))
EP210. 收購老藥廠是開發新藥的捷徑？這家台灣公司如何做到？ft.美商艾諾斯生技公司副總尤宗富
Manage episode 446554957 series 2904100
Content provided by 數位時代 Business Next. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by 數位時代 Business Next or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
在生技製藥業，開發新藥是最困難的一塊，從以往一款新藥平均花十年十億美金，到近年減到五年五億美金，仍是燒錢耗時的事。因此，從通過臨床二期或三期之後，新創公司把自己賣給大藥廠，減少後面通過FDA藥証的時間和金錢，成為一條捷徑。
台灣奈米碳素公司卻反其道而行，收購手上有多項專利和藥品、但營業額和市值已衰退的美國老藥廠艾諾斯，將其調整後推出改良款新藥，成功以小搏大，站穩市場。這一路是如何走來？
Powered by Firstory Hosting
723 episoade
Distribuie
